Authors: Adam Feuerstein and Matthew Herper
Published on April 16, 2020, in STAT Magazine
This article discusses some incredibly promising preliminary results from a clinical trial involving the treatment of severe COVID-19 patients with remdesivir, Gilead’s investigational antiviral drug.